HCV Patient Access: Trek Therapeutics Takes The Road Less Traveled

Trek Therapeutics, a three-year old biotech founded by a group of virology veterans, is testing the conventional wisdom in seeking to carve out a potential $17 billion business in the hotly contested hepatitis C space.